BC Extra | Jan 30, 2019
Company News

Allergan sheds $4.5B in market cap on 4Q18 earnings

Allergan plc (NYSE:AGN) lost $13.57 to $145.12 on Tuesday after it reported a $4.3 billion net loss in 4Q18 and presented 1Q19 guidance well below the Street’s consensus. The stock move translates to a loss...
BioCentury | Dec 31, 2016

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Extra | Nov 5, 2015
Company News

Allergan strikes dry eye deal with Mimetogen

Allergan plc (NYSE:AGN) reported 3Q15 earnings and licensed dry eye candidate tavilermide ( MIM-D3 ) from Mimetogen Pharmaceuticals Inc. (Montreal, Quebec). Allergan did not give an update regarding merger talks with Pfizer Inc. (NYSE:PFE), which were disclosed...
BC Week In Review | Jul 13, 2015
Company News

Kythera sales and marketing update

Kythera launched Kybella deoxycholic acid in the U.S. to reduce submental (under chin) fat. The drug is a synthetic sodium deoxycholate . Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH), Calabasas, Calif.   Business: Dermatology  ...
BC Week In Review | Jun 22, 2015
Company News

Kythera, Allergan deal

Allergan will acquire Kythera for about $2.1 billion in a cash and stock deal. Kythera shareholders will receive $60 per share in cash plus $15 per share in Allergan common shares. The $75 per share...
BC Extra | Jun 18, 2015
Company News

Allergan acquires Kythera for $2.1 billion

Allergan plc (NYSE:AGN) will acquire Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) for $75 per share, or about $2.1 billion in cash and stock. The price represents a 24% premium over Tuesday's closing price of $60.72. The deal...
BC Week In Review | May 4, 2015
Clinical News

Kybella deoxycholic acid regulatory update

FDA approved an NDA from Kythera for Kybella deoxycholic acid to improve the appearance of moderate to severe convexity or fullness associated with submental (under chin) fat. Kythera expects to begin training physicians in June...
BC Extra | Apr 30, 2015
Company News

FDA approves Kythera's double-chin treatment

FDA approved an NDA for Kybella deoxycholic acid from Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) to reduce submental (under chin) fat. FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted 17-0 in March to back Kybella's approval....
Items per page:
1 - 9 of 9